Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

24 Jun 2026, 22:50 UTC · 1h ago

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Recursion Pharmaceuticals (RXRX) is forecasted to report a quarterly revenue of $11.99 million, representing a 37.64% decrease compared to the year-ago quarter. — A significant double-digit decline in year-over-year revenue typically signals weakening business momentum or a shrinking market for the company's primary offerings.
-0.50
2
RXRX is forecasted to report a quarterly EPS of -$0.25, which is a 39.02% improvement over the corresponding quarter from the previous year. — Reducing losses (narrowing the EPS deficit) is a positive sign of operational efficiency or cost management in a biotechnology company.
+0.30
3
Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a neutral outlook with no strong conviction for an immediate price move in either direction.
+0.00